New drug study may yield hope for people with Type 1 diabetes
Researchers are recruiting candidates for a pilot study of a drug with the potential to reduce or eliminate the need for insulin injections.
Vancouver, BC, April 21, 2015 – Researchers at the University of British Columbia (UBC) and BCDiabetes are conducting a pilot clinical trial of a drug that has the potential to reduce or eliminate the need for insulin injections in people with recently diagnosed Type 1 diabetes. This study has been featured in many news pieces throughout BC.
Over the next year, BCDiabetes is recruiting 20 male or female participants to join the trial, aged 18-35, who have been diagnosed with Type 1 diabetes within the last 100 days.
The pilot clinical trial, referred to as UST1D, will investigate whether a drug called ustekinumab (known as “Stelara” commercially) can protect enough of the body’s own insulin-producing beta cells to delay or eliminate the need for insulin injections. Ustekinumab is approved and currently on the market in Canada for the treatment of psoriasis, and comes with extensive clinical and safety data.
“The study of ustekinumab to treat recently diagnosed Type 1 diabetes is among the most important we’ve conducted to date”, says Dr. Tom Elliott, endocrinologist and diabetes specialist at Vancouver General Hospital. “If it successfully prolongs or even eliminates the need for insulin injections, the lives of Type 1 diabetes patients will dramatically improve.”
Quick facts on the study:
UST1D is a 12-month study and is one of the first clinical trials to target the immune cells that cause Type 1 diabetes.
The study looks at the potential for the study drug ustekinumab to reduce insulin doses or even allow cessation of insulin shots in individuals with recently diagnosed Type 1 diabetes.
UST1D will compare the safety and effectiveness of ustekinumab at two different doses and two different frequencies of injections.
Ustekinumab is already approved by Health Canada for treatment of psoriasis, but is not currently approved safe for people with Type 1 diabetes.
All participants will receive ustekinumab at no charge.
This clinical trial is funded by the by the JDRF Canadian Clinical Trials Network (CCTN) and sponsored by the University of British Columbia.
If you want to check your eligibility for this study or need more information, please contact:
Dr. Marla Inducil – 604-628-7253 x7011 or email@example.com
“The launch of this pilot study marks an exciting time for Type 1 diabetes research in British Columbia”, says Dr. Jan Dutz, Professor, UBC Department of Dermatology and Skin Science, and principal investigator for the clinical trial. “As one of the first clinical trials to target the immune cells that cause Type 1 diabetes, we are hopeful that this treatment will be a step towards finding a way to stop or slow the destruction of the body’s own insulin-producing cells.”
Please see the following for additional information regarding the study, enrollment, and informed consent:Back To Top ▻